Adolescent nicotine induces depressive and anxiogenic effects through ERK 1-2 and Akt-GSK-3 pathways and neuronal dysregulation in the nucleus accumbens

Addict Biol. 2021 Mar;26(2):e12891. doi: 10.1111/adb.12891. Epub 2020 Mar 5.

Abstract

Long-term tobacco dependence typically develops during adolescence and neurodevelopmental nicotine exposure is associated with affective disturbances that manifest as a variety of neuropsychiatric comorbidities in clinical and preclinical studies, including mood and anxiety-related disorders. The nucleus accumbens shell (NASh) is critically involved in regulating emotional processing, and both molecular and neuronal disturbances in this structure are associated with mood and anxiety-related pathologies. In the present study, we used a rodent model of adolescent neurodevelopmental nicotine exposure to examine the expression of several molecular biomarkers associated with mood/anxiety-related phenotypes. We report that nicotine exposure during adolescence (but not adulthood) induces profound upregulation of the ERK 1-2 and Akt-GSK-3 signalling pathways directly within the NASh, as well as downregulation of local D1R expression that persists into adulthood. These adaptations were accompanied by decreases in τ, α, β, and γ-band oscillatory states, hyperactive medium spiny neuron activity with depressed bursting rates, and anxiety and depressive-like behavioural abnormalities. Pharmacologically targeting these molecular and neuronal adaptations revealed that selective inhibition of local ERK 1-2 and Akt-GSK-3 signalling cascades rescued nicotine-induced high-γ-band oscillatory signatures and phasic bursting rates in the NASh, suggesting that they are involved in mediating adolescent nicotine-induced depressive and anxiety-like neuropathological trajectories.

Keywords: GSK-3; adolescence; anxiety; nicotine; nucleus accumbens; oscillations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Animals
  • Anxiety / etiology*
  • Anxiety / pathology
  • Biomarkers
  • Depression / etiology*
  • Depression / pathology
  • Dose-Response Relationship, Drug
  • Glycogen Synthase Kinase 3 / drug effects*
  • Humans
  • Male
  • Nicotine / pharmacology*
  • Nucleus Accumbens / drug effects*
  • Phenotype
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction / drug effects
  • Tobacco Use Disorder / pathology

Substances

  • Biomarkers
  • Nicotine
  • Glycogen Synthase Kinase 3

Grants and funding